Literature DB >> 12796364

Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy.

Federica Moschella1, Brygida Bisikirska, Antonella Maffei, Kyriakos P Papadopoulos, Donna Skerrett, Zhuoru Liu, Charles S Hesdorffer, Paul E Harris.   

Abstract

PURPOSE: In this study, we have compared patterns of gene expression and functional activity of human dendritic cells (DCs) cultured under defined conditions in IFN-alpha-2b and recombinant human granulocyte macrophage colony-stimulating factor (DCA) with cells grown in granulocyte macrophage colony-stimulating factor and IL-4 (DC4) as an initial step in evaluating the clinical utility of DCA in cancer immunotherapy. EXPERIMENTAL DESIGN AND
RESULTS: Comparison of mRNA transcript profiles between DCA and DC4 revealed different expression patterns for cytokines, chemokines, chemokine receptors, costimulatory molecules, and adhesion proteins. Many genes involved in antigen (Ag) processing were equally expressed in both populations; however, expression of transcripts involved in Ag presentation was increased in DCA. DCA also showed up-regulation of Toll-like receptor 2 and 3, as well as several tumor necrosis factor family ligands. Consistent with expression profiling, functional assays demonstrated that DCAs were more potent stimulators of naive T-cell responses than DC4 in an interleukin 15 and interleukin 1beta-dependent manner. DCA-mediated tumor cell-directed cytotoxicity induced apoptosis in different human tumor cell lines and internalized apoptotic bodies to a greater extent than DC4. Lastly, in vitro priming experiments, using apoptotic cells or peptide as sources of Ag, showed that DCA drove the expansion of tumor peptide Ag-specific autologous CD8+ T cells to a greater extent than DC4.
CONCLUSIONS: The unique phenotype conferred by culturing DCs in IFN-alpha-2b may be useful in adoptive transfer regimens where the destruction of tumor cells in situ, initiation of T-cell responses toward tumor tissue with unknown Ags, and/or enhancement of pre-existing Ag-specific memory responses are desired outcomes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796364

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells.

Authors:  Martin D Hyrcza; Colin Kovacs; Mona Loutfy; Roberta Halpenny; Lawrence Heisler; Stuart Yang; Olivia Wilkins; Mario Ostrowski; Sandy D Der
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

2.  Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha.

Authors:  Jason M Zimmerer; Gregory B Lesinski; Amy S Ruppert; Michael D Radmacher; Carl Noble; Kari Kendra; Michael J Walker; William E Carson
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

3.  Interferon-α abrogates tolerance induction by human tolerogenic dendritic cells.

Authors:  Nicole Bacher; Edith Graulich; Helmut Jonuleit; Stephan Grabbe; Kerstin Steinbrink
Journal:  PLoS One       Date:  2011-07-27       Impact factor: 3.240

Review 4.  Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.

Authors:  Guido Antonelli; Carolina Scagnolari; Federica Moschella; Enrico Proietti
Journal:  Cytokine Growth Factor Rev       Date:  2014-12-30       Impact factor: 7.638

Review 5.  Gene Expression Profiling of Human Monocyte-derived Dendritic Cells - Searching for Molecular Regulators of Tolerogenicity.

Authors:  Katina Schinnerling; Paulina García-González; Juan Carlos Aguillón
Journal:  Front Immunol       Date:  2015-10-19       Impact factor: 7.561

6.  Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study.

Authors:  Francesca Urbani; Virginia Ferraresi; Imerio Capone; Iole Macchia; Belinda Palermo; Carmen Nuzzo; Angela Torsello; Patrizio Pezzotti; Diana Giannarelli; Anna Fausta Pozzi; Mariano Santaquilani; Paolo Roazzi; Silvia Bastucci; Caterina Catricalà; Antonia La Malfa; Giuseppe Vercillo; Novella Gualtieri; Carla Buccione; Luciano Castiello; Francesco Cognetti; Paola Nisticò; Filippo Belardelli; Federica Moschella; Enrico Proietti
Journal:  Front Oncol       Date:  2020-03-06       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.